Back to News
Feb 24, 2026 8:01 AM

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds

Additional capital further supports clinical development of ALV‑100, ALV‑200 and continued advancement of differentiated amylin‑based pipeline

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. ("Alveus"), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced the second and final closing of its oversubscribed Series A financing, increasing the total round size to $197 million. The second closing includes participation from Jeito Capital, Novo Holdings, and additional healthcare-focused funds, joining the original Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego ...